Comparative Pharmacology
Head-to-head clinical analysis: AGGRASTAT versus TICLID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AGGRASTAT versus TICLID.
AGGRASTAT vs TICLID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tirofiban is a reversible antagonist of glycoprotein IIb/IIIa receptor, inhibiting platelet aggregation by blocking fibrinogen binding.
Ticlopidine is a thienopyridine ADP receptor antagonist that irreversibly inhibits the P2Y12 receptor on platelets, preventing ADP-induced platelet aggregation.
A loading dose of 25 mcg/kg administered intravenously over 3 minutes, followed by a maintenance infusion of 0.15 mcg/kg/min for up to 18 hours. For patients with severe renal impairment (GFR <30 mL/min), the maintenance infusion rate is reduced to 0.075 mcg/kg/min.
250 mg orally twice daily
None Documented
None Documented
Terminal half-life: ~2 hours; clinical context: requires continuous IV infusion for sustained antiplatelet effect
Terminal elimination half-life is approximately 30-50 hours (mean ~33 hours), with clinical effects lasting 7-10 days after discontinuation due to irreversible platelet binding.
Renal: 65% unchanged drug; biliary/fecal: minimal (<5%)
Primarily hepatic metabolism; 60% renal as metabolites, 23% fecal. Minimal parent drug excreted unchanged.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent